Medtronic says it's done with a global user evaluation of a new closed-loop insulin pump with predictive low glucose management technology.
Medtronic (NYSE:MDT) said today that it's done with a global user evaluation program for a next-generation insulin pump system as it pursues the Holy Grail of diabetes: The artificial pancreas.
Medtronic CEO Omar Ishrak speaks with Lifescience Alley CEO Shaye Mandle at LSA2014.
Here's a look at some of the top Wall Street stories for medical device companies this week: Year in review: 2014 was the year of the medtech IPO; Symmetry Medical closes surgical spinout, OEM sale; Inogen affirms 2014 outlook, predicts 2015 growth of up to 25%
, Johnson & Johnson
, Nevro Corp.
, Ocular Therapeutix Inc.
, Symmetry Medical Inc.
, Symmetry Surgical
, Tecomet Inc.
Google Ventures, the VC arm of the Silicon Valley tech monolith, pumped more than ⅓ of its venture spend into healthcare and life science startups during 2014.
Google (NSDQ:GOOG) took a bigger bet on healthcare in 2014, investing more than ⅓ of the its venture dollars in healthcare and life science interests, according to the company and published reports.
Medtronic says its proposed, $43 billion acquisition of Covidien has cleared all anti-trust hurdles worldwide, setting the stage for shareholder votes next month.
Here's a look at some of the top regulatory stories for medical device companies this week: Cianna Medical wins FDA nod for breast surgery device; St. Jude Medical wins CE Mark for Quadra Allure MP pacemaker; Medtronic wins FDA approval for more Attain Performa quad defib leads; FDA postpones panel meeting for VertiFlex's Superion spine device; Report: FDA doesn't disclose most adviser's ties to medtech
Medtronic launches its 1st chitosan-based nasal packing, NovaShield, for use in functional endoscopic sinus surgeries.
Medtronic (NYSE:MDT) said today that it's launching a new sinus surgery device, NovaShield, for functional endoscopic sinus surgery.